Results 1 to 10 of about 822 (110)
Ceftazidime/Avibactam Resistance in Carbapenemase-Producing Klebsiella pneumoniae
Emerging Infectious Diseases, 2023 We identified a novel ceftazidime/avibactam resistance mechanism in sequence type 11 Klebsiella pneumoniae carbapenemase 2–producing K. pneumoniae.
Qiaozhen Cui +6 more
doaj +2 more sources
Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis [PDF]
Frontiers in Pharmacology, 2021 Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.Methods: PubMed, Embase, Web of ...
Dan Li +8 more
doaj +3 more sources
Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China [PDF]
Clinical Microbiology and Infection, 2020 The aim was to investigate the activity of ceftazidime/avibactam (CAZ/AVI) against carbapenem-resistant Klebsiella pneumoniae (CRKP) and identify the resistance mechanisms before CAZ/AVI coming to Chinese market.Clinical CRKP isolates were continuously collected from 36 tertiary hospitals in China from 1 March 2017 to 31 July 2017.
Quan Shi, Xueqing Wu, Murat áková
exaly +3 more sources
Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam
WIREs Mechanisms of Disease, 2022 AbstractCeftazidime/avibactam (CAZ/AVI), a combination of ceftazidime and a novel β‐lactamase inhibitor (avibactam) that has been approved by the U.S. Food and Drug Administration, the European Union, and the National Regulatory Administration in China. CAZ/AVI is used mainly to treat complicated urinary tract infections and complicated intra‐abdominal
Yanzi Zhou, Yonghong Xiao
exaly +3 more sources
Resistance to ceftazidime–avibactam and underlying mechanisms
Journal of Global Antimicrobial Resistance, 2020 Ceftazidime-avibactam (CAZ-AVI) is a novel synthetic β-lactamase inhibitor combination. Although the combination has been available clinically for only a few years, cases of resistance to CAZ-AVI have already been reported.In the present review, we summarize the distribution of CAZ-AVI-resistant strains and the possible resistance mechanisms.There are ...
Jin Wang, Yun Cai
exaly +4 more sources
Frontiers in Microbiology, 2022 This study reported the identification of a novel ceftazidime-avibactam-resistant KPC-2 variant, KPC-123, in a Citrobacter koseri isolated from a patient in a Chinese hospital following ceftazidime-avibactam treatment of infection caused by OXA-232 ...
Lin Wang +3 more
doaj +3 more sources
Diagnostic Microbiology and Infectious DiseaseWe described the emergence of ceftazidime/avibactam and cefiderocol cross-resistance in patients with KPC-producing Klebsiella pneumoniae infections. All strains with ceftazidime/avibactam and cefiderocol cross-resistance showed point mutations on KPC Ω-loop.
Maddalena Giannella +2 more
exaly +3 more sources
Ceftazidime-avibactam in ceftazidime-resistant infections [PDF]
The Lancet Infectious Diseases, 2016 One of the important causes of the development of resistance to β-lactam drugs is their overuse. β-lactamase inhibitors have been combined with many β-lactam drugs to resume their efficacy since the emergence of multidrugresistant organisms. Yahuda Carmeli and colleagues recommended the combination of ceftazidimeavibactam as a potential alternative to ...
Yehuda, Carmeli +4 more
openaire +5 more sources
Antibiotics, 2021 Ceftazidime/avibactam uniquely demonstrates activity against both KPC and OXA-48-like carbapenemase-expressing Enterobacterales. Clinical resistance to ceftazidime/avibactam in KPC-producers was foreseen in in-vitro resistance studies.
Snehal Palwe +5 more
doaj +1 more source
In vitro Optimization of Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae
Frontiers in Microbiology, 2021 Ceftazidime/avibactam is an important treatment option for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp), however, resistance can emerge during treatment.
Yanqin Huang +8 more
doaj +1 more source